ScienceChina rushes to develop Moderna-style cancer vaccines amid market frenzy

Hong Kong-listed Chinese biotechnology companies have seen their shares surge after Moderna’s breakthrough cancer vaccine trial. Firms including Jiangsu Hengrui Pharmaceuticals and Li Ka-shing-backed CK Life Sciences are advancing similar programmes, targeting a potentially large market as cancer deaths in China approach 2.6 million a year.

cancer vaccinesChinese biotechModerna

SSouth China Morning Post★★★☆☆2026-08-26 01:00Original